论文部分内容阅读
目的:评价肝动脉经皮股动脉植入化疗泵灌注中西药治疗晚期原发性肝癌的临床疗效。方法:以生存期为观察指标,采用同期非随机对照方法,对2007年3月～2010年10月接受经皮股动脉植入动脉化疗泵灌注中西药的16例中晚期原发性肝癌患者(治疗组)与对症营养支持治疗的16例患者(对照组)比较,观察两组的生存期缓解差异。结果:治疗组与对照组中位生存期分别为20个月(6～29)、4个月(2～8),治疗组生存期长于对照组(P<0.05)。结论:经皮股动脉植入化疗泵灌注中西药能提高中晚期原发性肝癌患者的远期生存率,提高患者生存质量,延缓肝癌复发进展,延长患者的生命。
OBJECTIVE: To evaluate the clinical efficacy of transcatheter arterial grafting of hepatic artery with chemotherapy pump in the treatment of advanced primary liver cancer. Methods: Sixty-six patients with advanced primary liver cancer who underwent percutaneous femoral arterial infusion with traditional Chinese medicine and western medicine during March 2007 to October 2010 were enrolled in this study. Treatment group) and symptomatic nutritional support treatment of 16 patients (control group), observed differences in the survival of the two groups. Results: The median survival time was 20 months (6 to 29) and 4 months (2 to 8) in the treatment group and the control group, respectively. The survival time of the treatment group was longer than that of the control group (P <0.05). Conclusion: Percutaneous transcatheter arterial infusion of Chinese and western medicine can improve the long-term survival rate of patients with primary liver cancer in the advanced stage, improve the quality of life, delay the recurrence of liver cancer and prolong the life of patients.